Cell therapy startup Wugen has secured $115 million led by Fidelity to advance its allogeneic CAR-T therapy (WU-CART-007) targeting relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoma. Unlike autologous CAR-Ts, Wugen’s off-the-shelf approach uses donor cells to treat any eligible patient, aiming for a scalable, convenient cancer treatment. A pivotal clinical trial is underway, with regulatory submissions expected in 2027. This financing comes despite a challenging investment environment for cell therapies and follows Wugen’s prior $172 million Series B funding in 2021. The company seeks to offer a potentially curative option for patients with limited therapies.